MX395231B - Compuestos eficaces en el tratamiento de la hepatotoxicidad y enfermedades de hígado graso, y uso de los mismos. - Google Patents
Compuestos eficaces en el tratamiento de la hepatotoxicidad y enfermedades de hígado graso, y uso de los mismos.Info
- Publication number
- MX395231B MX395231B MX2018003700A MX2018003700A MX395231B MX 395231 B MX395231 B MX 395231B MX 2018003700 A MX2018003700 A MX 2018003700A MX 2018003700 A MX2018003700 A MX 2018003700A MX 395231 B MX395231 B MX 395231B
- Authority
- MX
- Mexico
- Prior art keywords
- hepatotoxicity
- fatty liver
- treatment
- liver diseases
- compounds effective
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
- C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/16—Preparation of carboxylic acids or their salts, halides or anhydrides by oxidation
- C07C51/21—Preparation of carboxylic acids or their salts, halides or anhydrides by oxidation with molecular oxygen
- C07C51/215—Preparation of carboxylic acids or their salts, halides or anhydrides by oxidation with molecular oxygen of saturated hydrocarbyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/34—Esters of acyclic saturated polycarboxylic acids having an esterified carboxyl group bound to an acyclic carbon atom
- C07C69/42—Glutaric acid esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
- C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
- C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
- C07H13/06—Fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562222959P | 2015-09-24 | 2015-09-24 | |
| US201562257697P | 2015-11-19 | 2015-11-19 | |
| PCT/CN2016/078039 WO2017084234A1 (zh) | 2015-11-19 | 2016-03-31 | 预防或治疗脂肪肝的药物组合物 |
| PCT/CN2016/100187 WO2017050298A1 (en) | 2015-09-24 | 2016-09-26 | Compounds effective in treating hepatotoxicity and fatty liver diseases and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018003700A MX2018003700A (es) | 2018-08-01 |
| MX395231B true MX395231B (es) | 2025-03-25 |
Family
ID=60047309
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018003700A MX395231B (es) | 2015-09-24 | 2016-09-26 | Compuestos eficaces en el tratamiento de la hepatotoxicidad y enfermedades de hígado graso, y uso de los mismos. |
| MX2022007816A MX2022007816A (es) | 2015-09-24 | 2018-03-23 | Compuestos eficaces en el tratamiento de la hepatotoxicidad y enfermedades de higado graso, y uso de los mismos. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022007816A MX2022007816A (es) | 2015-09-24 | 2018-03-23 | Compuestos eficaces en el tratamiento de la hepatotoxicidad y enfermedades de higado graso, y uso de los mismos. |
Country Status (20)
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015070396A1 (zh) * | 2013-11-13 | 2015-05-21 | 财团法人国防教育研究基金会 | 无肝副作用的对乙酰胺基酚新复方组合 |
| EA201890810A1 (ru) | 2015-09-24 | 2018-11-30 | Синью Фарма Инк. | Соединения, эффективные для лечения гепатотоксичности и стеатоза печени, и их применение |
| CN107613968A (zh) * | 2015-11-19 | 2018-01-19 | 欣耀生医股份有限公司 | 预防或治疗脂肪肝的药物组合物 |
| US20210008101A1 (en) * | 2018-02-14 | 2021-01-14 | Sinew Pharma Inc. | Methods and compositions for preventing, reducing or eradicating toxicity caused by acetaminophen (apap) |
| CN110538187A (zh) * | 2018-05-28 | 2019-12-06 | 北京大学 | Cpt1激活剂 |
| KR102136326B1 (ko) * | 2018-09-06 | 2020-07-22 | 서울대학교산학협력단 | 가시박으로부터 분리한 플라보노이드 유도체를 유효성분으로 포함하는 간 질환 예방 또는 치료용 조성물 |
| TWI691719B (zh) * | 2018-10-19 | 2020-04-21 | 香港商阿瓦隆 海帕波有限公司 | 半乳糖快速定量檢測系統及其應用 |
| CN109920550A (zh) * | 2018-12-25 | 2019-06-21 | 天津大学 | 一种基于dMRI研究青少年肌阵挛性癫痫的方法 |
| KR20210138579A (ko) * | 2019-01-21 | 2021-11-19 | 싱가포르 헬스 서비시즈 피티이 엘티디 | 간독성의 치료 |
| CN110269855A (zh) * | 2019-07-19 | 2019-09-24 | 辽宁大学 | 黄酮类小分子化合物在制备抑制胰脂肪酶活性药物中的应用 |
| US12383191B1 (en) * | 2020-05-04 | 2025-08-12 | PathAI, Inc. | Systems and methods for assessing liver pathology |
| CN113999272A (zh) * | 2021-10-29 | 2022-02-01 | 广西医科大学 | 香蜂草苷的制备方法及其应用 |
| CN113875982A (zh) * | 2021-11-19 | 2022-01-04 | 武汉森澜生物科技有限公司 | 一种含二氢杨梅素的抗衰组合物及其应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4661519A (en) * | 1983-04-12 | 1987-04-28 | Pola Chemical Industries Inc. | Method for dermatological application |
| CH664150A5 (de) * | 1985-01-15 | 1988-02-15 | Peter Paul Prof Dr Speiser | Fumarsaeureprodrug, verfahren zu seiner herstellung und dieses enthaltende darreichungsformen. |
| JP3916685B2 (ja) * | 1996-02-29 | 2007-05-16 | 第一製薬株式会社 | ガラクトース誘導体 |
| JP4677550B2 (ja) * | 2002-08-14 | 2011-04-27 | 独立行政法人産業技術総合研究所 | 環状エステル化合物 |
| TWI287990B (en) * | 2004-01-08 | 2007-10-11 | Nat Defense Medical Ct | Inhibitors and enhancers of uridine diphosphate-glucuronosyl transferase 2B (UGT2B) |
| WO2006010083A2 (en) * | 2004-07-08 | 2006-01-26 | Molecular Therapeutics, Inc. | Biodegradable nanoparticles |
| CN1939929A (zh) * | 2005-09-29 | 2007-04-04 | 云南白药集团股份有限公司 | 一种偏诺皂苷类化合物酸式盐及制备方法 |
| US8969312B2 (en) * | 2011-04-20 | 2015-03-03 | National Defense Education And Research Foundation | Low side effect pharmaceutical composition containing antituberculosis drugs |
| KR20150084897A (ko) * | 2012-11-12 | 2015-07-22 | 세게티스, 인코포레이티드. | 가교성 폴리케탈 에스터, 그의 제조 방법 및 용도 |
| US9211298B2 (en) * | 2012-11-16 | 2015-12-15 | Song Gao | Compositions containing enriched natural crocin and/or crocetin, and their therapeutic or nutraceutical uses |
| MX2015014956A (es) * | 2013-04-29 | 2016-08-08 | Chigurupati Tech Private Ltd | Toxicidad reducida en bebidas alcoholicas. |
| TWI552748B (zh) | 2013-10-25 | 2016-10-11 | The use of a compound for the removal of hepatotoxicity against Acetaminophen (APAP) | |
| CN104623670A (zh) * | 2013-11-06 | 2015-05-20 | 高松 | 一种含西红花素的组合物及其应用 |
| WO2015070396A1 (zh) | 2013-11-13 | 2015-05-21 | 财团法人国防教育研究基金会 | 无肝副作用的对乙酰胺基酚新复方组合 |
| CN104292289B (zh) * | 2014-07-10 | 2017-12-29 | 程怡 | 半乳糖配体及其在肝靶向脂质体中的应用 |
| EA201890810A1 (ru) * | 2015-09-24 | 2018-11-30 | Синью Фарма Инк. | Соединения, эффективные для лечения гепатотоксичности и стеатоза печени, и их применение |
| CN107613968A (zh) * | 2015-11-19 | 2018-01-19 | 欣耀生医股份有限公司 | 预防或治疗脂肪肝的药物组合物 |
-
2016
- 2016-09-26 EA EA201890810A patent/EA201890810A1/ru unknown
- 2016-09-26 WO PCT/CN2016/100187 patent/WO2017050298A1/en not_active Ceased
- 2016-09-26 EP EP25188784.0A patent/EP4609911A3/en active Pending
- 2016-09-26 TW TW105131118A patent/TWI781912B/zh active
- 2016-09-26 EP EP21173210.2A patent/EP3991724B1/en active Active
- 2016-09-26 HR HRP20250899TT patent/HRP20250899T1/hr unknown
- 2016-09-26 CA CA3232521A patent/CA3232521A1/en active Pending
- 2016-09-26 HK HK18103735.4A patent/HK1244266A1/zh unknown
- 2016-09-26 CN CN202510528240.7A patent/CN120398980A/zh active Pending
- 2016-09-26 CA CA2999368A patent/CA2999368A1/en active Pending
- 2016-09-26 CN CN201680020530.XA patent/CN107614475A/zh active Pending
- 2016-09-26 CN CN202510506442.1A patent/CN120349362A/zh active Pending
- 2016-09-26 KR KR1020187011548A patent/KR102891137B1/ko active Active
- 2016-09-26 EP EP16848179.4A patent/EP3353144A4/en active Pending
- 2016-09-26 US US15/564,526 patent/US10456371B2/en active Active
- 2016-09-26 AU AU2016327930A patent/AU2016327930B2/en active Active
- 2016-09-26 ES ES21173210T patent/ES3044383T3/es active Active
- 2016-09-26 BR BR112018005905-6A patent/BR112018005905B1/pt active IP Right Grant
- 2016-09-26 JP JP2018535221A patent/JP2018537517A/ja active Pending
- 2016-09-26 HU HUE21173210A patent/HUE072982T2/hu unknown
- 2016-09-26 SG SG10202002573RA patent/SG10202002573RA/en unknown
- 2016-09-26 MY MYPI2018701141A patent/MY190647A/en unknown
- 2016-09-26 KR KR1020247008968A patent/KR20240042148A/ko active Pending
- 2016-09-26 MX MX2018003700A patent/MX395231B/es unknown
-
2018
- 2018-03-23 PH PH12018500659A patent/PH12018500659A1/en unknown
- 2018-03-23 MX MX2022007816A patent/MX2022007816A/es unknown
- 2018-04-11 ZA ZA2018/02373A patent/ZA201802373B/en unknown
-
2019
- 2019-09-17 US US16/573,506 patent/US11285123B2/en active Active
-
2021
- 2021-07-14 AU AU2021205040A patent/AU2021205040B2/en active Active
- 2021-10-28 JP JP2021176691A patent/JP7261850B2/ja active Active
-
2022
- 2022-03-03 US US17/686,013 patent/US12083088B2/en active Active
-
2024
- 2024-02-14 AU AU2024200963A patent/AU2024200963A1/en active Pending
- 2024-06-13 US US18/742,433 patent/US20240335404A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX395231B (es) | Compuestos eficaces en el tratamiento de la hepatotoxicidad y enfermedades de hígado graso, y uso de los mismos. | |
| JOP20190194A1 (ar) | مركبات نيوكليوتيدات ثنائية حلقية لعلاج السرطان | |
| MX2018011216A (es) | Moléculas pequeñas contra cereblon para mejorar la función efectora de los linfocitos t. | |
| EA201790273A1 (ru) | Флагеллиновые композиции и их применение | |
| CL2016002027A1 (es) | Ciclopropilamina como inhibidor de la lsd1 | |
| MX2018005315A (es) | Composiciones y metodos para el tratamiento del cancer. | |
| MX2018004515A (es) | Agentes de anticuerpo especificos para cd19 humano y usos de los mismos. | |
| CO2017005784A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
| EA201890204A1 (ru) | Антибактериальные соединения | |
| CO2017007121A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
| MX386935B (es) | Profármacos de fumaratos y su uso en el tratamiento de diferentes enfermedades. | |
| EA201692526A1 (ru) | Замещенные [1,2,4]триазольные соединения | |
| CL2016003074A1 (es) | Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer. | |
| MX2016009590A (es) | Composiciones de apilimod y métodos para usar las mismas. | |
| MX2021000773A (es) | Composiciones que comprenden acido 15-hidroxieicosapentaenoico (15-hepe) y metodos de uso del mismo. | |
| MX2019013808A (es) | Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer. | |
| MX374385B (es) | Apilimod para uso en el tratamiento de melanoma. | |
| CL2016001937A1 (es) | Compuestos de benzopirano funcionalizados y uso de los mismos | |
| MX2019001634A (es) | Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos. | |
| CO2018008249A2 (es) | Composiciones terapéuticas y métodos para el tratamiento de la hepatitis b | |
| DOP2016000297A (es) | Composiciones farmacéuticas útiles para tratar enfermedades infecciosas | |
| MX2018005987A (es) | Compuestos heterociclicos para el tratamiento de enfermedades. | |
| MX2016014166A (es) | Compuestos de triaminopirimidina utiles para evitar o tratar la malaria. | |
| PL3373922T3 (pl) | Kompozycje i sposoby do stosowania do leczenia homocystynurii | |
| MX2021002444A (es) | Compuestos y metodos para el tratamiento de infecciones fungicas. |